TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer — Stella

Recruiting

Back to Esophageal Cancer trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

Netherlands

Academic Medical Center, Amsterdam

Key details

Phase

Large-scale testing

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Enrollment target

~376 participants

Started

March 2022

Primary completion

July 2027

Age range

18 Years and older

Last updated June 2022

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov